LINKÖPING, Sweden,
Dec. 6,
2024 /PRNewswire/ -- SyntheticMR, leader in
quantitative imaging software, is pleased to announce that its
SyMRI 15 solution has obtained 510(k) clearance from the U.S. Food
and Drug Administration (FDA) on diagnostic image replacement of
conventional images.
SyMRI 15 offers an innovative approach to MRI, transforming
traditional imaging methodologies with its advanced synthetic
imaging technology. Clinically validated through extensive
multi-center studies across leading institutions in the United States, SyMRI 15 has proven its
capability to enhance imaging workflows by replacing conventional
3D imaging techniques in addition to its unique ability to provide
tissue quantification. This technology offers significant gains in
both efficiency and throughput while maintaining the highest
standards of diagnostic accuracy.
CONTACT:
For additional information, please contact Vedran
Beglerbegovic, acting CEO, SyntheticMR AB, +46 79 077 27
20 vedran.beglerbegovic@syntheticmr.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/syntheticmr-ab/r/syntheticmr-receives-fda-510-k--clearance-for-symri-15,c4078158
The following files are available for download:
|
https://mb.cision.com/Main/11663/4078158/3158232.pdf
|
Release
|
View original
content:https://www.prnewswire.com/news-releases/syntheticmr-receives-fda-510k-clearance-for-symri-15-302325245.html
SOURCE SyntheticMR AB